A Depressive Endophenotype of Mild Cognitive Impairment and Alzheimer’s Disease
Open Access
- 11 July 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7) , e68848
Abstract
Alzheimer’s disease (AD) is a devastating public health problem that affects over 5.4 million Americans. Depression increases the risk of Mild Cognitive Impairment (MCI) and AD. By understanding the influence of depression on cognition, the potential exists to identify subgroups of depressed elders at greater risk for cognitive decline and AD. The current study sought to: 1) clinically identify a sub group of geriatric patients who suffer from depression related cognitive impairment; 2) cross validate this depressive endophenotype of MCI/AD in an independent cohort. Data was analyzed from 519 participants of Project FRONTIER. Depression was assessed with the GDS30 and cognition was assessed using the EXIT 25 and RBANS. Five GDS items were used to create the Depressive endophenotype of MCI and AD (DepE). DepE was significantly negatively related to RBANS index scores of Immediate Memory (B=-2.22, SE=.37, p<0.001), visuospatial skills (B=-1.11, SE=0.26, p<0.001), Language (B=-1.03, SE=0.21, p<0.001), Attention (B=-2.56, SE=0.49, p<0.001), and Delayed Memory (B=-1.54, SE = 037, p<0.001), and higher DepE scores were related to poorer executive functioning (EXIT25; B=0.65, SE=0.19, p=0.001). DepE scores significantly increased risk for MCI diagnosis (odds ratio [OR] = 2.04; 95% CI=1.54-2.69). Data from 235 participants in the TARCC (Texas Alzheimer’s Research & Care Consortium) were analyzed for cross-validation of findings in an independent cohort. The DepE was significantly related to poorer scores on all measures, and a significantly predicted of cognitive change over 12- and 24-months. The current findings suggest that a depressive endophenotype of MCI and AD exists and can be clinically identified using the GDS-30. Higher scores increased risk for MCI and was cross-validated by predicting AD in the TARCC. A key purpose for the search for distinct subgroups of individuals at risk for AD and MCI is to identify novel treatment and preventative opportunities.Keywords
This publication has 58 references indexed in Scilit:
- Cognitive Outcomes After Sertaline Treatment in Patients With Depression of Alzheimer DiseaseThe American Journal of Geriatric Psychiatry, 2012
- Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humansProceedings of the National Academy of Sciences, 2011
- A Serum Protein–Based Algorithm for the Detection of Alzheimer DiseaseArchives of Neurology, 2010
- Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD miceNeuropharmacology, 2010
- Utility of the RBANS in detecting cognitive impairment associated with Alzheimer's disease: Sensitivity, specificity, and positive and negative predictive powersArchives of Clinical Neuropsychology, 2008
- Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes ScoresArchives of Neurology, 2008
- APOE genotype predicts depression in women with Alzheimer's disease: a retrospective studyInternational Journal of Geriatric Psychiatry, 2007
- Depression and Risk for Alzheimer DiseaseArchives of General Psychiatry, 2006
- Depressive Symptoms, Vascular Disease, and Mild Cognitive ImpairmentArchives of General Psychiatry, 2006
- Development and validation of a geriatric depression screening scale: A preliminary reportJournal of Psychiatric Research, 1982